세계의 경구 단백질 및 펩티드 시장 : 분자별, 약제 클래스별, 치료 영역별, 투약형별 - 예측(-2029년)

The global oral proteins and peptides market is projected to reach USD 20.36 billion by 2029 from USD 7.38 billion in 2024, at a CAGR of 22.5% during the forecast period of 2024 to 2029. The growth of the oral proteins and peptides market has been significantly driven by its increasing demand of oral peptides for the treatment of chronic diseases such as diabetes and CNS disorders, increasing R&D investment by key players for the development and launch of innovative oral peptides and continuous advancements in drug delivery technologies. However, high development cost and the hurdles in formulation and stability are restraining market growth.

"The semaglutide molecule segment accounted for the largest share by molecule in 2023."

In 2023, the semaglutide segment accounted for the largest share by molecule in the global oral proteins and peptides market. Semaglutide is an analogue of glucagon-like peptide-1 (GLP-1), a hormone involved in regulating blood sugar levels and appetite. It is used for the management of type-2 diabetes and obesity. Semaglutide works by enhancing insulin secretion in response to elevated blood glucose, reducing glucagon release (which raises blood sugar), and promoting a feeling of fullness after eating, which can help reduce food intake. Oral semaglutide (Rybelsus) is the first oral glucagon-like peptide 1 (GLP-1) receptor agonist product approved by the US FDA for the treatment of type 2 diabetes. As a class, GLP-1 receptor agonists are widely used and recommended for the management of type 2 diabetes.

"The US has continued to dominate the oral proteins and peptides market during the forecast period of 2024-2029."

The US is the world's largest biopharmaceutical market and a leader in biopharmaceutical research/investments. Driven by the growing patient population suffering from infectious disease, increasing biopharmaceuticals' importance, and the necessity of safe and high-quality products in the healthcare sector, growing investments and funding in biomedical research by government bodies and pharmaceutical & biotechnology companies. Early adoption of emerging technologies and alternative therapies, supported by the availability of the majority of oral proteins and peptides in the region, further supports market growth. Also, a strong established presence of several market players in the region is another key factor supporting market growth. These key companies include, Novo Nordisk A/S (Denmark), AbbVie, Inc. (US), Pfizer Inc. (US)

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side- 70% and Demand Side 30%
• By Designation: Managers - 45%, CXO & Directors - 30%, and Executives - 25%
• By Region: North America -40%, Europe -25%, Asia-Pacific -25%, Latin America -5% and Middle East & Africa- 5%

List of key Companies Profiled in the Report:

Novo Nordisk A/S (Denmark), AbbVie Inc. (US), Pfizer Inc. (US), Acadia Pharmaceuticals Inc (US), Aurinia Pharmaceuticals Inc. (Canada), Bausch Health Companies Inc (Canada), CHIESI Farmaceutici S.p.A. (Italy), EnteraBio LTD. (Israel), Merck & Co., Inc. (US), Johnson & Johnson Services, Inc. (US), R-Pharm JSC (Russia), Proxima Concepts (US), and SWK Holdings Corporation (US)

Research Coverage:

This research report categorizes the oral proteins and peptides market by molecule (Trofinetide, Semaglutide, Linaclotide, Voclosporin, Plecanatide, Calcitonin, and Others), by Drug Class (Analog of Glycine-Proline-Glutamate (GPE), Glucagon Like Peptide-1 (GLP-1) Receptor Agonist, Guanylate Cyclase-C Agonists, Calcineurin-Inhibitor Immunosuppressant, Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonist, and Others), by Therapeutic Area (Genetic Disorder, Diabetes, Nephrology, Gastroenterology, CNS Disorders, Obesity & Overweight, and Others) by Formulation (Tablet, Capsules, and Oral Solution), by End User (Home Care Settings, Long-Term Care Facilities, Hospitals & Specialty Clinics) and by region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the oral proteins and peptides market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products, solutions, key strategies, collaborations, partnerships, and agreements. New launches, collaborations and acquisitions, and recent developments associated with the oral proteins and peptides market.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall oral proteins and peptides market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

• Analysis of key drivers (Rising Prevalence of Chronic Diseases such as diabetes, gastroenterology diseases and kidney diseases, Advancements in Drug Delivery Technologies, Patient Preference and Compliance for oral route of drug administration, Increasing adoption of inorganic growth strategies such as collaboration and agreement), restraints (High cost is associated with drug development, Contraindication of oral proteins and peptides, Stringent regulatory approval process), opportunities (Robust clinical trial pipeline for oral proteins and peptides drug, Growing demand for non-invasive and patient-friendly treatment options), and Challenges (Hurdles in formulation and stability, Availability of alternative therapies) influencing the growth of the market).
• Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and new product launches in the oral proteins and peptides market.
• Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the oral proteins and peptides market
• Competitive Assessment: In-depth assessment of market shares, growth strategies and product offerings of leading players. A detailed analysis of the key industry players has been done to provide insights into their key strategies, product launches/ approvals, pipeline analysis, acquisitions, partnerships, agreements, collaborations, other recent developments, investment and funding activities, brand/product comparative analysis, and vendor valuation and financial metrics of the oral proteins and peptides market.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 MARKET SCOPE
  • 1.3.1 MARKETS COVERED
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 STAKEHOLDERS

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
  • 2.1.2 PRIMARY DATA
• 2.2 MARKET SIZE ESTIMATION
  • 2.2.1 INSIGHTS FROM PRIMARIES
  • 2.2.2 MARKET SIZE ASSESSMENT AT SEGMENT LEVEL
• 2.3 MARKET GROWTH FORECAST
• 2.4 MARKET BREAKDOWN & DATA TRIANGULATION
• 2.5 STUDY ASSUMPTIONS
• 2.6 RESEARCH LIMITATIONS
• 2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 ORAL PROTEINS & PEPTIDES MARKET OVERVIEW
• 4.2 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET SHARE, BY FORMULATION AND COUNTRY (2023)
• 4.3 ORAL PROTEINS & PEPTIDES MARKET SHARE, BY THERAPEUTIC AREA, 2023
• 4.4 ORAL PROTEINS & PEPTIDES MARKET SHARE, BY END USER, 2024 VS. 2029
• 4.5 ORAL PROTEINS & PEPTIDES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Increasing burden of chronic diseases
    • 5.2.1.2 Advancements in drug delivery technologies
    • 5.2.1.3 Higher patient compliance and preference for oral route
    • 5.2.1.4 Expanding therapeutic applications of oral proteins & peptides
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 High cost of drug development
    • 5.2.2.2 Contraindication of oral proteins & peptides
    • 5.2.2.3 Stringent regulatory approval process
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Robust clinical trial pipeline for oral proteins & peptides
    • 5.2.3.2 Growing demand for personalized medicine
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Hurdles in formulation and stability
    • 5.2.4.2 Availability of alternative therapies
• 5.3 ECOSYSTEM ANALYSIS
  • 5.3.1 ROLE OF RAW MATERIAL VENDORS
  • 5.3.2 ROLE OF PRODUCT PROVIDERS
  • 5.3.3 ROLE OF END USERS
  • 5.3.4 ROLE OF REGULATORY AUTHORITIES
• 5.4 VALUE CHAIN ANALYSIS
• 5.5 SUPPLY CHAIN ANALYSIS
• 5.6 PORTER'S FIVE FORCES ANALYSIS
  • 5.6.1 THREAT OF NEW ENTRANTS
  • 5.6.2 THREAT OF SUBSTITUTES
  • 5.6.3 BARGAINING POWER OF SUPPLIERS
  • 5.6.4 BARGAINING POWER OF BUYERS
  • 5.6.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.7 KEY STAKEHOLDERS & BUYING CRITERIA
  • 5.7.1 KEY STAKEHOLDERS
  • 5.7.2 BUYING CRITERIA
• 5.8 PRICING ANALYSIS
  • 5.8.1 PRICING ANALYSIS OF ORAL PROTEIN & PEPTIDE PRODUCTS
  • 5.8.2 PRICING ANALYSIS OF TOP ORAL PROTEINS & PEPTIDES, BY COUNTRY AND REGION
• 5.9 REGULATORY LANDSCAPE
  • 5.9.1 REGULATORY SCENARIO
  • 5.9.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 5.10 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.11 TECHNOLOGY ANALYSIS
  • 5.11.1 KEY TECHNOLOGIES
    • 5.11.1.1 Transient permeation enhancer
    • 5.11.1.2 Gastrointestinal permeation enhancement technology
    • 5.11.1.3 Oral sCT (OSTORA) technology
  • 5.11.2 COMPLEMENTARY TECHNOLOGIES
    • 5.11.2.1 Peptelligence
    • 5.11.2.2 ThioMatrix
    • 5.11.2.3 Transferrin-based recombinant fusion protein
  • 5.11.3 ADJACENT TECHNOLOGIES
    • 5.11.3.1 Oramed and Orasome
    • 5.11.3.2 Q-sphera
    • 5.11.3.3 Nanoinclusion
    • 5.11.3.4 Oleotec and Soctec
• 5.12 PIPELINE ANALYSIS
• 5.13 PATENT ANALYSIS
  • 5.13.1 METHODOLOGY
  • 5.13.2 INNOVATION AND PATENT APPLICATIONS
  • 5.13.3 TOP APPLICANTS
• 5.14 KEY CONFERENCES & EVENTS, 2024-2025
• 5.15 INVESTMENT & FUNDING SCENARIO
• 5.16 IMPACT OF AI ON ORAL PROTEINS & PEPTIDES MARKET

6 ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE

• 6.1 INTRODUCTION
• 6.2 SEMAGLUTIDE
  • 6.2.1 INCREASED PATIENT COMPLIANCE TO BOOST MARKET GROWTH
• 6.3 CALCITONIN
  • 6.3.1 NEED FOR EFFECTIVE ANTI-MIGRAINE DRUGS TO SUPPORT ADOPTION
• 6.4 LINACLOTIDE
  • 6.4.1 RISING PREVALENCE OF GASTRIC DISORDERS TO SUPPORT GROWTH
• 6.5 TROFINETIDE
  • 6.5.1 FDA APPROVAL TO SUPPORT GROWTH
• 6.6 VOCLOSPORIN
  • 6.6.1 INCREASING REGULATORY APPROVALS TO DRIVE PATIENT ACCESS AND ADOPTION
• 6.7 PLECANATIDE
  • 6.7.1 INCREASED PATIENT CONVENIENCE TO SUPPORT GROWTH
• 6.8 OTHER MOLECULES

7 ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS

• 7.1 INTRODUCTION
• 7.2 GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS
  • 7.2.1 INCREASING ADOPTION TO SUPPORT GROWTH
• 7.3 CALCITONIN GENE-RELATED PEPTIDE RECEPTOR ANTAGONISTS
  • 7.3.1 INCREASING PREVALENCE OF MIGRAINE TO DRIVE ADOPTION
• 7.4 GUANYLATE CYCLASE-C AGONISTS
  • 7.4.1 RISING PREVALENCE OF IBS, CIC TO DRIVE MARKET
• 7.5 GLYCINE-PROLINE-GLUTAMATE
  • 7.5.1 FOCUS ON DEVELOPING GPE-CLASS DRUGS TO SUPPORT GROWTH
• 7.6 CALCINEURIN-INHIBITOR IMMUNOSUPPRESSANTS
  • 7.6.1 INCREASING NUMBER OF ORGAN TRANSPLANTS TO PROMOTE GROWTH
• 7.7 OTHER DRUG CLASSES

8 ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA

• 8.1 INTRODUCTION
• 8.2 DIABETES
  • 8.2.1 HIGH EFFICACY TO SUPPORT END-USER ADOPTION
• 8.3 CNS DISORDERS
  • 8.3.1 GROWING BURDEN OF NEUROLOGICAL DISORDERS TO PROPEL MARKET
• 8.4 GASTROENTEROLOGY
  • 8.4.1 RISING PREVALENCE OF GASTROINTESTINAL DISORDERS TO SUPPORT SEGMENT GROWTH
• 8.5 GENETIC DISORDERS
  • 8.5.1 GROWING PREVALENCE OF GENETIC DISORDERS TO SUPPORT GROWTH
• 8.6 NEPHROLOGY
  • 8.6.1 RISING PREVALENCE OF KIDNEY DISORDERS IN GERIATRIC POPULATION TO PROPEL MARKET
• 8.7 OBESITY & OVERWEIGHT
  • 8.7.1 RISING INCIDENCE OF OBESITY TO PROPEL MARKET GROWTH
• 8.8 OTHER THERAPEUTIC AREAS

9 ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION

• 9.1 INTRODUCTION
• 9.2 TABLETS
  • 9.2.1 HIGH ADOPTION AND EASE OF ADMINISTRATION TO SUPPORT GROWTH
• 9.3 CAPSULES
  • 9.3.1 RISING DEMAND FOR ORAL BIOLOGICS AND INCREASED PATIENT COMPLIANCE TO DRIVE MARKET
• 9.4 ORAL SOLUTIONS
  • 9.4.1 GROWING FOCUS ON IMPROVING BIOAVAILABILITY AND PATIENT CONVENIENCE TO SUPPORT MARKET GROWTH

10 ORAL PROTEINS & PEPTIDES MARKET, BY END USER

• 10.1 INTRODUCTION
• 10.2 HOME CARE SETTINGS
  • 10.2.1 RISING NUMBER OF TELEHEALTH COMPANIES AND CONVENIENCE OF HOME CARE TO SUPPORT MARKET GROWTH
• 10.3 LONG-TERM CARE FACILITIES
  • 10.3.1 RISING GERIATRIC POPULATION AND PREVALENCE OF CHRONIC DISEASES TO SUPPORT GROWTH
• 10.4 HOSPITALS & SPECIALTY CLINICS
  • 10.4.1 ADOPTION OF ORAL PEPTIDES FOR VARIED INDICATIONS TO SUPPORT MARKET GROWTH

11 ORAL PROTEINS & PEPTIDES MARKET, BY REGION

• 11.1 INTRODUCTION
• 11.2 NORTH AMERICA
  • 11.2.1 NORTH AMERICA: MACROECONOMIC OUTLOOK
  • 11.2.2 US
    • 11.2.2.1 US to hold large share of North American and global markets
  • 11.2.3 CANADA
    • 11.2.3.1 Increasing prevalence of obesity and heart failure to support market growth
• 11.3 EUROPE
  • 11.3.1 EUROPE: MACROECONOMIC OUTLOOK
  • 11.3.2 GERMANY
    • 11.3.2.1 Germany to hold largest share of European market
  • 11.3.3 UK
    • 11.3.3.1 Strong focus on advancement of life sciences to support market growth
  • 11.3.4 FRANCE
    • 11.3.4.1 Growing prevalence of diabetes and government initiatives to boost market growth
  • 11.3.5 ITALY
    • 11.3.5.1 Presence of major pharmaceutical and biotechnology companies to drive market
  • 11.3.6 SPAIN
    • 11.3.6.1 Initiatives associated with GLP-1 drugs to drive market
  • 11.3.7 NETHERLANDS
    • 11.3.7.1 Rising awareness and focus on pharmaceutical R&D to support market growth
  • 11.3.8 REST OF EUROPE
• 11.4 ASIA PACIFIC
  • 11.4.1 ASIA PACIFIC: MACROECONOMIC OUTLOOK
  • 11.4.2 CHINA
    • 11.4.2.1 Increasing R&D expenditure to drive market
  • 11.4.3 JAPAN
    • 11.4.3.1 Increasing prevalence of diabetes to drive market
  • 11.4.4 INDIA
    • 11.4.4.1 Strong initiatives to develop cost-effective and patient-friendly medications to aid market growth
  • 11.4.5 AUSTRALIA
    • 11.4.5.1 Rising access to GLP-1 drugs and government support to drive market
  • 11.4.6 SOUTH KOREA
    • 11.4.6.1 Growing focus on development of innovative treatment solutions to propel market growth
  • 11.4.7 REST OF ASIA PACIFIC
• 11.5 LATIN AMERICA
  • 11.5.1 LATIN AMERICA: MACROECONOMIC OUTLOOK
  • 11.5.2 BRAZIL
    • 11.5.2.1 Brazil to hold largest market share in Latin America
  • 11.5.3 MEXICO
    • 11.5.3.1 Growing diabetes and obesity cases to support market growth
  • 11.5.4 REST OF LATIN AMERICA
• 11.6 MIDDLE EAST
  • 11.6.1 MIDDLE EAST: MACROECONOMIC OUTLOOK
  • 11.6.2 GCC COUNTRIES
    • 11.6.2.1 Saudi Arabia
      • 11.6.2.1.1 Growing availability of GLP-1 drugs to support market growth
    • 11.6.2.2 UAE
      • 11.6.2.2.1 Growing regulatory approvals for GLP-1 drugs to propel market
    • 11.6.2.3 Rest of GCC countries
  • 11.6.3 REST OF MIDDLE EAST
• 11.7 AFRICA
  • 11.7.1 LARGE AND GROWING PATIENT POPULATION, FAVORABLE HEALTHCARE REFORMS TO DRIVE MARKET
  • 11.7.2 AFRICA: MACROECONOMIC OUTLOOK

12 COMPETITIVE LANDSCAPE

• 12.1 OVERVIEW
• 12.2 KEY STRATEGIES/RIGHT TO WIN
  • 12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN ORAL PROTEINS & PEPTIDES
• 12.3 REVENUE SHARE ANALYSIS
• 12.4 MARKET SHARE ANALYSIS
• 12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
  • 12.5.1 STARS
  • 12.5.2 EMERGING LEADERS
  • 12.5.3 PERVASIVE PLAYERS
  • 12.5.4 PARTICIPANTS
• 12.6 COMPANY EVALUATION MATRIX: PLAYERS WITH PRODUCTS IN PIPELINE, 2023
  • 12.6.1 STARS
  • 12.6.2 EMERGING LEADERS
  • 12.6.3 PERVASIVE PLAYERS
  • 12.6.4 PARTICIPANTS
  • 12.6.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
    • 12.6.5.1 Company Footprint
    • 12.6.5.2 Molecule footprint
    • 12.6.5.3 Formulation footprint
    • 12.6.5.4 Therapeutic area footprint
    • 12.6.5.5 Region footprint
• 12.7 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
  • 12.7.1 PROGRESSIVE COMPANIES
  • 12.7.2 RESPONSIVE COMPANIES
  • 12.7.3 DYNAMIC COMPANIES
  • 12.7.4 STARTING BLOCKS
  • 12.7.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
    • 12.7.5.1 Detailed list of key startups/SMEs
    • 12.7.5.2 Competitive benchmarking of key startups/SMEs
• 12.8 VALUATION & FINANCIAL METRICS
  • 12.8.1 FINANCIAL METRICS
  • 12.8.2 COMPANY VALUATION
• 12.9 BRAND/PRODUCT COMPARISON
• 12.10 COMPETITIVE SCENARIO
  • 12.10.1 PRODUCT APPROVALS
  • 12.10.2 DEALS
  • 12.10.3 EXPANSIONS
  • 12.10.4 OTHER DEVELOPMENTS

13 COMPANY PROFILES

• 13.1 INTRODUCTION
• 13.2 KEY PLAYERS
  • 13.2.1 NOVO NORDISK A/S
    • 13.2.1.1 Business overview
    • 13.2.1.2 Products offered
    • 13.2.1.3 Recent developments
      • 13.2.1.3.1 Product launches & approvals
      • 13.2.1.3.2 Expansions
      • 13.2.1.3.3 Other developments
    • 13.2.1.4 MnM view
      • 13.2.1.4.1 Right to win
      • 13.2.1.4.2 Strategic choices
      • 13.2.1.4.3 Weaknesses & competitive threats
  • 13.2.2 ABBVIE INC.
    • 13.2.2.1 Business overview
    • 13.2.2.2 Products offered
    • 13.2.2.3 Recent developments
      • 13.2.2.3.1 Product approvals
    • 13.2.2.4 MnM view
      • 13.2.2.4.1 Right to win
      • 13.2.2.4.2 Strategic choices
      • 13.2.2.4.3 Weaknesses & competitive threats
  • 13.2.3 PFIZER INC.
    • 13.2.3.1 Business overview
    • 13.2.3.2 Product pipeline
    • 13.2.3.3 Recent developments
      • 13.2.3.3.1 Product approvals
      • 13.2.3.3.2 Deals
      • 13.2.3.3.3 Other developments
    • 13.2.3.4 MnM view
      • 13.2.3.4.1 Right to win
      • 13.2.3.4.2 Strategic choices
      • 13.2.3.4.3 Weaknesses & competitive threats
  • 13.2.4 BAUSCH HEALTH COMPANIES INC.
    • 13.2.4.1 Business overview
    • 13.2.4.2 Products offered
    • 13.2.4.3 Recent developments
      • 13.2.4.3.1 Product approvals
  • 13.2.5 CHIESI FARMACEUTICI S.P.A.
    • 13.2.5.1 Business overview
    • 13.2.5.2 Products offered
    • 13.2.5.3 Recent developments
      • 13.2.5.3.1 Deals
  • 13.2.6 ACADIA PHARMACEUTICALS INC.
    • 13.2.6.1 Business overview
    • 13.2.6.2 Products offered
    • 13.2.6.3 Recent developments
      • 13.2.6.3.1 Product approvals
  • 13.2.7 AURINIA PHARMACEUTICALS INC.
    • 13.2.7.1 Business overview
    • 13.2.7.2 Products offered
    • 13.2.7.3 Recent developments
      • 13.2.7.3.1 Product approvals
  • 13.2.8 MERCK & CO., INC.
    • 13.2.8.1 Business overview
    • 13.2.8.2 Product pipeline
    • 13.2.8.3 Recent developments
      • 13.2.8.3.1 Other developments
  • 13.2.9 JOHNSON & JOHNSON SERVICES, INC.
    • 13.2.9.1 Business overview
    • 13.2.9.2 Product pipeline
    • 13.2.9.3 Recent developments
      • 13.2.9.3.1 Other developments
  • 13.2.10 SWK HOLDINGS
    • 13.2.10.1 Business overview
    • 13.2.10.2 Product pipeline
    • 13.2.10.3 Recent developments
      • 13.2.10.3.1 Other developments
  • 13.2.11 R-PHARM JSC
    • 13.2.11.1 Business overview
    • 13.2.11.2 Products in pipeline
  • 13.2.12 ENTERA BIO LTD.
    • 13.2.12.1 Business overview
    • 13.2.12.2 Product pipeline
    • 13.2.12.3 Recent developments
      • 13.2.12.3.1 Deals
      • 13.2.12.3.2 Other developments
  • 13.2.13 PROXIMA CONCEPTS
    • 13.2.13.1 Business overview
    • 13.2.13.2 Products in pipeline
• 13.3 OTHER PLAYERS
  • 13.3.1 ASTRAZENECA PLC
  • 13.3.2 REGOR THERAPEUTICS GROUP
  • 13.3.3 TERNS PHARMACEUTICALS, INC.
  • 13.3.4 STRUCTURE THERAPEUTICS
  • 13.3.5 VIKING THERAPEUTICS
  • 13.3.6 PROTAGONIST THERAPEUTICS INC.
  • 13.3.7 RANI THERAPEUTICS
  • 13.3.8 CARMOT THERAPEUTICS, INC.
  • 13.3.9 ZEALAND PHARMA
  • 13.3.10 SCIWIND BIOSCIENCES CO., LTD.
  • 13.3.11 JIANGSU HENGRUI PHARMACEUTICALS CO., LTD.

14 APPENDIX

• 14.1 DISCUSSION GUIDE
• 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 14.3 CUSTOMIZATION OPTIONS
• 14.4 RELATED REPORTS
• 14.5 AUTHOR DETAILS